Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Cryosite Limited ( (AU:CTE) ) just unveiled an update.
Cryosite Limited held its Annual General Meeting, where all resolutions, including the adoption of the remuneration report, the company’s option plan, and the re-election of a director, were carried with significant support. This outcome reflects strong shareholder confidence in the company’s strategic direction and governance, potentially enhancing its market position and stakeholder trust.
The most recent analyst rating on (AU:CTE) stock is a Hold with a A$1.00 price target. To see the full list of analyst forecasts on Cryosite Limited stock, see the AU:CTE Stock Forecast page.
More about Cryosite Limited
Cryosite is an Australian company specializing in outsourced clinical trials depot services. Established in 2000, the company excels in clinical trial logistics, managing importation, storage, distribution, and reverse logistics for temperature-sensitive products. Their team consists of highly qualified scientists and clinical trials experts, ensuring efficient and safe trial operations.
Average Trading Volume: 6,159
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$42.95M
For an in-depth examination of CTE stock, go to TipRanks’ Overview page.